CymaBay Therapeutics: Funding, Investors & Team (Oct 2026)
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.
CymaBay Therapeutics has raised $260M across 3 funding rounds on record, the most recent an undisclosed round of $85.0M announced in Jan 2023.
That round is above the $8.1M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
CymaBay Therapeutics Company Profile and Key Stats
Latest funding round on record: Jan 2023.
CymaBay Therapeutics Funding Rounds
CymaBay Therapeutics raised $100M in a Post-IPO Debt announced in Aug 2021.
3 months later, a Post-IPO Debt of $75.0M was announced in Nov 2021.
1.2 years later, an undisclosed round of $85.0M was announced in Jan 2023.
CymaBay Therapeutics Founders and Leadership Team
Contact details for the CymaBay Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →CymaBay Therapeutics Funding Compared to Other Biotechnology Startups
CymaBay Therapeutics' latest round of $85.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like CymaBay Therapeutics in Biotechnology and Hayward
Companies Similar to CymaBay Therapeutics
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Circle Pharma is a biotechnology company in the initial stages of development that uses unique computational…
Evvy is for people with vaginas who want to be empowered with information about their microbiome. Their…
CymaBay Therapeutics Funding FAQs
What does CymaBay Therapeutics do?
CymaBay Therapeutics is a clinical-stage biopharmaceutical company located in the San Francisco Bay Area focused on the development and commercialization of proprietary new medicines for important human diseases. We are committed to developing breakthrough medicines that improve the lives of patients and their families. CymaBay was seeded with the assets from an earlier metabolic disease company in which more than $120M was invested to produce a robust pipeline. Arhalofenate is a novel oral small molecule being developed to treat the approximately 1 million gout patients that flare three or more times per year. Gout flares are painful inflammatory episodes caused by crystals of monosodium urate (MSU) that result from excess serum uric acid (sUA). In three Phase 2 studies in gout patients arhalofenate was shown to reduce the incidence and duration of flares while simultaneously lowering sUA. If confirmed in additional clinical studies, arhalofenate’s dual acting profile would be unique since all other urate lowering therapies paradoxically increase flares as they lower sUA over the first 6 to 12 months of treatment. Increased flares lead many patients to stop or avoid treatment leading to progression of disease with pain and suffering, erosion of joint structure and functionality, lost time from work, and increased healthcare costs.
How much funding has CymaBay Therapeutics raised?
CymaBay Therapeutics has raised $260M across 3 rounds on record. The most recent is an undisclosed round of $85.0M announced in Jan 2023.
When did CymaBay Therapeutics last raise funding?
CymaBay Therapeutics' most recent funding round on record is an undisclosed round of $85.0M, announced in Jan 2023.
Who is the CEO of CymaBay Therapeutics?
Sujal Shah is listed as CEO at CymaBay Therapeutics.
Where is CymaBay Therapeutics headquartered?
CymaBay Therapeutics is based in Hayward, California, United States.
How many employees does CymaBay Therapeutics have?
CymaBay Therapeutics is in the 51-100 employee band.
How does CymaBay Therapeutics' funding compare to other Biotechnology startups?
CymaBay Therapeutics' latest round of $85.0M is above the $8.1M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's CymaBay Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for CymaBay Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.